Trial Profile
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary)
- Indications Liver metastases; Neuroendocrine tumours
- Focus Therapeutic Use
- 25 Sep 2023 Planned End Date changed from 1 Mar 2024 to 1 Sep 2024.
- 25 Sep 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 03 May 2022 Status changed from recruiting to active, no longer recruiting.